Efficacy and safety of oral anticoagulants in young ischemic stroke patients with non-valvular atrial fibrillation
10.3760/cma.j.issn.1671-7368.2017.10.013
- VernacularTitle:伴非瓣膜病心房颤动青年缺血性脑卒中患者口服抗凝治疗的疗效观察
- Author:
Kai WANG
1
;
Xiu'e WEI
;
Liangqun RONG
;
Lijie XIAO
;
Tengfei LIU
Author Information
1. 徐州医学院第二附属医院神经内科
- Keywords:
Heart valve diseases;
Young;
Warfarin;
Dabigatran
- From:
Chinese Journal of General Practitioners
2017;16(10):796-799
- CountryChina
- Language:Chinese
-
Abstract:
Seventy two iscbemic stroke patients aged 18-45 years with nonvalvular atrial fibrillation treated in the Second Affiliated Hospital of Xuzhou Medical College from April 2014 to August 2016 were assigned to warfarin group (n =36) and dabigatran group (n =36).In warfarin group the oral warfarin started from small dose and maintained international normalized ratio (INR) as 2.0 to 3.0.In dabigatran group 110 mg dabigatran etexilate was given b.i.d.All patients were followed up for one year after treatment.Medication was discontinued in 10 cases (28％) of warfarin group and 2 cases (6％) of dabigatran group one year after treatment (P =0.02).There were 8 (22％) cases of thromboembolic events in warfarin group and 1 (3％) case in dabigatran group (P =0.03).In warfarin group 233 INR values were recorded with an average of 2.32,and the percentage of time in therapeutic range (TTR) was 75％ (174/ 233).There were 2 deaths in warfarin group and no death in dabiga group.There were 19 (53％) cases of adverse reactions in warfarin group,including 9 cases of bleeding (6 mild bleeding and 3 serious bleeding),5 cases of nausea and vomiting,2 cases constipation or diarrhea,3 cases of headache and dizziness.There were 6 (17％) cases of adverse reactions in dabigatran group,including 2 cases of mild bleeding,2 cases of nausea and vomiting,2 cases of constipation or diarrhea.There was significant difference in the incidence of adverse reactions between the two groups(x2 =13.3,P ＜ 0.01).The results indicate that the efficacy and safety of dabigatran is superior to that of warfarin for young ischemic stroke patients with nonvalvular atrial fibrillation.
